Using data from a large ovarian cancer registry, a research team from Roswell Park Comprehensive Cancer Center uncovered a link between testicular cancer and familial ovarian cancer that may be attributable to genetic factors on the X chromosome.
The National Comprehensive Cancer Network has released a new NCCN Clinical Practice Guidelines in Oncology intended to help make sure people living with HIV who are diagnosed with cancer receive safe, necessary treatment.
CancerCare published a white paper highlighting perspectives from oncology providers on the importance and utility of including patient priorities in treatment decisions.
One third of men with lymph node-positive penile cancer don't receive a lymph node dissection, the recommended care associated with an overall survival advantage, researchers from Fox Chase Cancer Center have found. The paper appears in JAMA Oncology.
The New England Journal of Medicine Feb. 22 published data for larotrectinib in the treatment of pediatric and adult patients whose tumors harbor tropomyosin receptor kinase gene fusions. Loxo Oncology Inc. and Bayer AG are developing the agent
Guidelines developed collaboratively by the American Society of Clinical Oncology and the National Comprehensive Cancer Network offer clinicians recommendations for assessment and management of side effects related to immune checkpoint inhibitors.
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
A new study from the University of Wisconsin Carbone Cancer Center highlights a disparity in cancer care: the depressed spouses of cancer patients are 33 percent less likely to receive adequate treatment for depression than are patients whose spouses don't have cancer. Couples who live in rural areas are 72 percent less likely to receive recommended care for depression (including medication and talk therapy) than the depressed spouses of those without cancer.
Genentech announced results from the positive phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Bristol-Myers Squibb Company said the ongoing phase III CheckMate-227 study met its co-primary endpoint of progression-free survival with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high (≥10 mutations/megabase, mut/mb) tumor mutation burden, regardless of PD-L1 expression.
